[{"indications": "Indications\u00a0severe refractory eczema [unlicensed\r\nindication]; inflammatory bowel disease (section 1.5.3); autoimmune conditions and prophylaxis\r\nof transplant rejection (section 8.2.1); rheumatoid arthritis (section 10.1.3)", "name": "AZATHIOPRINE - PREPARATIONS FOR ECZEMA AND PSORIASIS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "AZATHIOPRINE"], "cautions": "Cautions\u00a0section 8.2.1", "side-effects": "Side-effects\u00a0section 8.2.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/204281.htm", "doses": ["Severe refractory eczema [unlicensed indication], by mouth, normal or high TPMT activity, 1\u20133\u00a0mg/kg daily;\r\nintermediate TPMT activity, 0.5\u20131.5\u00a0mg/kg daily"], "pregnancy": "Pregnancy\u00a0section 8.2.1"}, {"indications": "Indications\u00a0\n(From 8.2.1 Antiproliferative immunosuppressants: British National Formulary)\nThiopurine methyltransferaseThe enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.; inflammatory bowel disease [unlicensed\r\nindication] (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE); rheumatoid arthritis (%s\n(From Drugs affecting the immune response: British National Formulary)\nDrugs affecting the immune response); severe\r\nrefractory eczema [unlicensed indication] (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE)", "name": "AZATHIOPRINE - ANTIPROLIFERATIVE IMMUNOSUPPRESSANTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.1 Antiproliferative immunosuppressants", "AZATHIOPRINE"], "cautions": "Cautions\u00a0\n(From Immunosuppressant therapy: British National Formulary)\nBioavailabilityDifferent formulations of the same immunosuppressant may vary in bioavailability and to avoid reduced effect or excessive side-effects, it is important not to change formulation except on the advice of a transplant specialist.;\r\nthiopurine methyltransferase status (see notes above); monitor\r\nfor toxicity throughout treatment; monitor full blood\r\ncount weekly (more frequently with higher doses or if severe hepatic\r\nor renal impairment) for first 4 weeks (manufacturer advises weekly\r\nmonitoring for 8 weeks but evidence of practical value unsatisfactory),\r\nthereafter reduce frequency of monitoring to at least every 3 months; reduce dose in elderly; interactions: Appendix 1 (azathioprine)Bone marrow suppression\u00a0Patients\r\nshould be warned to report immediately any signs or symptoms of bone\r\nmarrow suppression e.g. inexplicable bruising or bleeding, infection", "side-effects": "Side-effects\u00a0hypersensitivity reactions (including malaise,\r\ndizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia,\r\nrash, hypotension and interstitial nephritis\u2014calling for immediate\r\nwithdrawal); dose-related bone marrow suppression (see also Cautions);\r\nliver impairment, cholestatic jaundice, hair loss and increased susceptibility\r\nto infections and colitis in patients also receiving corticosteroids;\r\nnausea; rarely pancreatitis, pneumonitis, hepatic\r\nveno-occlusive disease, lymphoma, red cell aplasia\u2014\n(From 8.2.1 Antiproliferative immunosuppressants: British National Formulary)\nMycophenolate mofetil  is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal, hepatic or cardiac transplantation when used in combination with ciclosporin and corticosteroids. There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher.Cases of pure red cell aplasia have been reported with azathioprine and with mycophenolate mofetil; dose reduction or discontinuation should be considered under specialist supervision.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4780.htm", "doses": ["By mouth, or (if\r\noral administration not possible\u2014intravenous solution very irritant,\r\nsee below) by intravenous injection over at least 1\r\nminute (followed by 50\u00a0mL sodium chloride intravenous\r\ninfusion), or by intravenous infusion", "Autoimmune conditions, 1\u20133\u00a0mg/kg daily, adjusted according to\r\nresponse (consider withdrawal if no improvement within 3 months)", "Suppression of transplant rejection, 1\u20132.5\u00a0mg/kg daily adjusted according\r\nto response", "Azathioprine doses in BNF may differ from\r\nthose in product literature", "Intravenous injection is alkaline and very irritant, intravenous route should therefore\r\nbe used only if oral route not feasible, see also\r\nAppendix 4"], "pregnancy": "Pregnancy\u00a0treatment should not generally be initiated during\r\npregnancy; see also Immunosuppressant therapy"}, {"indications": "Indications\u00a0\n(From 8.2.1 Antiproliferative immunosuppressants: British National Formulary)\nThiopurine methyltransferaseThe enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.; inflammatory bowel disease [unlicensed\r\nindication] (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE); rheumatoid arthritis (%s\n(From Drugs affecting the immune response: British National Formulary)\nDrugs affecting the immune response); severe\r\nrefractory eczema [unlicensed indication] (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE)", "name": "AZATHIOPRINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.1 Antiproliferative immunosuppressants", "AZATHIOPRINE"], "cautions": "Cautions\u00a0\n(From Immunosuppressant therapy: British National Formulary)\nBioavailabilityDifferent formulations of the same immunosuppressant may vary in bioavailability and to avoid reduced effect or excessive side-effects, it is important not to change formulation except on the advice of a transplant specialist.;\r\nthiopurine methyltransferase status (see notes above); monitor\r\nfor toxicity throughout treatment; monitor full blood\r\ncount weekly (more frequently with higher doses or if severe hepatic\r\nor renal impairment) for first 4 weeks (manufacturer advises weekly\r\nmonitoring for 8 weeks but evidence of practical value unsatisfactory),\r\nthereafter reduce frequency of monitoring to at least every 3 months; reduce dose in elderly; interactions: Appendix 1 (azathioprine)Bone marrow suppression\u00a0Patients\r\nshould be warned to report immediately any signs or symptoms of bone\r\nmarrow suppression e.g. inexplicable bruising or bleeding, infection", "side-effects": "Side-effects\u00a0hypersensitivity reactions (including malaise,\r\ndizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia,\r\nrash, hypotension and interstitial nephritis\u2014calling for immediate\r\nwithdrawal); dose-related bone marrow suppression (see also Cautions);\r\nliver impairment, cholestatic jaundice, hair loss and increased susceptibility\r\nto infections and colitis in patients also receiving corticosteroids;\r\nnausea; rarely pancreatitis, pneumonitis, hepatic\r\nveno-occlusive disease, lymphoma, red cell aplasia\u2014\n(From 8.2.1 Antiproliferative immunosuppressants: British National Formulary)\nMycophenolate mofetil  is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine. It is licensed for the prophylaxis of acute rejection in renal, hepatic or cardiac transplantation when used in combination with ciclosporin and corticosteroids. There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher.Cases of pure red cell aplasia have been reported with azathioprine and with mycophenolate mofetil; dose reduction or discontinuation should be considered under specialist supervision.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4780.htm", "doses": ["By mouth, or (if\r\noral administration not possible\u2014intravenous solution very irritant,\r\nsee below) by intravenous injection over at least 1\r\nminute (followed by 50\u00a0mL sodium chloride intravenous\r\ninfusion), or by intravenous infusion", "Autoimmune conditions, 1\u20133\u00a0mg/kg daily, adjusted according to\r\nresponse (consider withdrawal if no improvement within 3 months)", "Suppression of transplant rejection, 1\u20132.5\u00a0mg/kg daily adjusted according\r\nto response", "Azathioprine doses in BNF may differ from\r\nthose in product literature", "Intravenous injection is alkaline and very irritant, intravenous route should therefore\r\nbe used only if oral route not feasible, see also\r\nAppendix 4"], "pregnancy": "Pregnancy\u00a0treatment should not generally be initiated during\r\npregnancy; see also Immunosuppressant therapy"}, {"indications": "Indications\u00a0\n(From Drugs affecting the immune response: British National Formulary)\nDrugs affecting the immune response; inflammatory\r\nbowel disease [unlicensed indication] (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE); autoimmune conditions and prophylaxis\r\nof transplantation rejection (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE); severe refractory eczema [unlicensed\r\nindication] (%s\n(From AZATHIOPRINE: British National Formulary)\nAZATHIOPRINE)", "name": "AZATHIOPRINE - DRUGS THAT SUPPRESS THE RHEUMATIC DISEASE PROCESS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Drugs affecting the immune response", "AZATHIOPRINE"], "cautions": "Cautions\u00a0section 8.2.1", "side-effects": "Side-effects\u00a0section 8.2.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106293.htm", "doses": ["By mouth, initially, rarely more than 3\u00a0mg/kg\r\ndaily, reduced according to response; maintenance 1\u20133\u00a0mg/kg daily;\r\nconsider withdrawal if no improvement within 3 months"], "pregnancy": "Pregnancy\u00a0section 8.2.1"}, {"indications": "Indications\u00a0see under Inflammatory Bowel Disease; autoimmune conditions and\r\nprophylaxis of transplant rejection (section 8.2.1); rheumatoid arthritis (section 10.1.3); severe refractory eczema (section 13.5.3)", "name": "AZATHIOPRINE - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.3 Drugs affecting the immune response", "AZATHIOPRINE"], "cautions": "Cautions\u00a0section 8.2.1", "side-effects": "Side-effects\u00a0section 8.2.1", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201295.htm", "doses": ["Severe acute Crohn\u2019s disease, maintenance of remission\r\nof Crohn\u2019s disease or ulcerative colitis [unlicensed indications], adult over 18 years, by mouth, 2\u20132.5\u00a0mg/kg\r\ndaily; some patients may respond to lower doses"], "pregnancy": "Pregnancy\u00a0section 8.2.1"}]